Autoimmune Diseases: Clinical Trials

1,743 trials for Autoimmune Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

995 completed, 248 recruiting, 142 terminated, 122 unknown. 1743 Phase 1, 491 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11743Completed 995, Recruiting 248, Terminated 142, Unknown 122, Not yet recruiting 88, Withdrawn 70, Active not recruiting 66, Enrolling by invitation 7, Suspended 5
Phase 2491Completed 223, Recruiting 88, Unknown 52, Terminated 50, Not yet recruiting 28, Withdrawn 25, Active not recruiting 23, Enrolling by invitation 2

Follow Autoimmune Diseases: new trials by email Literature Review of Autoimmune Diseases trials Research Report on Autoimmune Diseases

Trials (filtered) newest first · largest first

All 1,743 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cannabichromene Safety in Rheumatoid Arthritis
Cannabichromene - Arthritis, Rheumatoid
Phase 1 / Phase 2WithdrawnCrystal Lederhos Smith2028-07-152026-09-23
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
CB-010 - Systemic Lupus Erythematosus, Lupus
Phase 1WithdrawnCaribou Biosciences, Inc.2027-12-012025-09-19
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
fetal MSCs combined with 4SCAR T cells - Autoimmune Diseases
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
CAR-T Cells Targeting Autoimmune Diseases
4SCAR T cells - Autoimmune Diseases
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis
Phase 1Not yet recruitingAbelZeta Inc.122027-03-012026-10-13
A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis
Orca-Q, myeloablative regimen, Tacrolimus - Primary Progressive Multiple Sclerosis, Multiple Sclerosis
Phase 1Not yet recruitingOrca Biosystems, Inc.102027-03-012026-11-13
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Phase 1 / Phase 2Not yet recruitingAbelZeta Inc.1192027-02-012026-10-13
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
RXIM002 - Immune Thrombocytopenia (ITP)
Phase 1Not yet recruitingRiboX Therapeutics Ltd.272027-02-012026-10-28
ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.
ENCRT-103-hPI encompasses the ENC-103 device, which will be implanted once loaded with primary islet cargo. - Type 1 Diabetes
Phase 1Not yet recruitingEncellin102027-01-062026-08-20
Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes
Teplizumab, Intralymphatic Insulin Immunotherapy (ILIT) - Type 1 Diabetes Mellitus (T1DM), Type 1 Diabetes Mellitus
Phase 1Not yet recruitingAbdullah Kars602027-01-012026-05-27
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus
Phase 1Not yet recruitingShenzhen MagicRNA Biotechnology Co., Ltd122026-12-312026-08-12
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
HN2301 injection - Generalized Myasthenia Gravis
Phase 1Not yet recruitingShenzhen MagicRNA Biotechnology Co., Ltd62026-12-312026-08-12
IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
IASO206 injection - Autoimmune Hemolytic Anemia, Relapsed/Refractory
Phase 1Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China182026-12-152026-11-05
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Phase 1Not yet recruitingGustave Roussy, Cancer Campus, Grand Paris62026-12-012026-09-02
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
CTA313 UCAR T Cell Infusion - Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS)
Phase 1Not yet recruitingImviva Bio812026-12-012026-08-24
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder
Phase 1 / Phase 2Not yet recruitingTianjin Medical University General Hospital202026-12-012026-10-16
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis
hUC-MSC suspension, Placebo - Rheumatoid Arthritis
Phase 1Not yet recruitingBaylx Inc.162026-12-012025-12-23
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
DKB903 - Rheumatoid Arthritis and Systemic Lupus Erythematosus
Phase 1Not yet recruitingNovartis Pharmaceuticals902026-12-012026-11-06

Showing 20 of 1743. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 1 (420)  ·  Arthritis, Rheumatoid (386)  ·  Lupus Erythematosus, Systemic (288)  ·  Multiple Sclerosis (251)  ·  Diabetes Mellitus (140)  ·  Lupus Nephritis (71)  ·  Purpura, Thrombocytopenic, Idiopathic (63)  ·  Multiple Sclerosis, Relapsing-Remitting (60)  ·  Scleroderma, Systemic (58)  ·  Multiple Sclerosis, Chronic Progressive (57)  ·  Sjogren's Syndrome (45)  ·  Myositis (40)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (39)  ·  Diabetes Mellitus, Type 2 (37)

Broader conditions

Immune System Diseases (1718)  ·  Skin and Connective Tissue Diseases (761)  ·  Connective Tissue Diseases (712)  ·  Musculoskeletal Diseases (483)  ·  Endocrine System Diseases (450)  ·  Joint Diseases (448)  ·  Rheumatic Diseases (443)  ·  Nutritional and Metabolic Diseases (437)  ·  Arthritis (427)  ·  Metabolic Diseases (426)  ·  Glucose Metabolism Disorders (418)  ·  Nervous System Diseases (415)  ·  Autoimmune Diseases of the Nervous System (356)  ·  Demyelinating Diseases (320)

Interventions

Cyclophosphamide (48)  ·  Insulin Aspart (41)  ·  Insulin Lispro (36)  ·  Rituximab (36)  ·  fludarabine (36)  ·  Insulin Glargine (29)  ·  Methotrexate (24)  ·  insulin degludec (23)  ·  Insulin (20)  ·  tocilizumab (20)  ·  Abatacept (16)  ·  Sodium Chloride (13)  ·  Etanercept (12)  ·  Methylprednisolone (12)  ·  Islets of Langerhans Transplantation (11)

Sponsors

Novo Nordisk A/S (85)  ·  GlaxoSmithKline (48)  ·  Eli Lilly and Company (43)  ·  Sanofi (36)  ·  Amgen (35)  ·  Bristol-Myers Squibb (30)  ·  AstraZeneca (28)  ·  Pfizer (28)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (24)  ·  Novartis Pharmaceuticals (19)  ·  Biogen (16)  ·  Adocia (14)  ·  Hoffmann-La Roche (14)  ·  Institute of Hematology & Blood Diseases Hospital, China (11)  ·  Jiangsu HengRui Medicine Co., Ltd. (11)

Countries

United States (718)  ·  China (271)  ·  Germany (217)  ·  United Kingdom (117)  ·  Australia (91)  ·  Spain (86)  ·  Canada (78)  ·  Poland (57)  ·  France (55)  ·  Italy (45)  ·  Japan (43)  ·  Netherlands (43)  ·  Belgium (42)  ·  South Korea (36)  ·  Russia (30)

Top investigators

Richard Burt, MD (10)

Results publications

PMID 28205039, PMID 31072380, PMID 30402720, PMID 34628605, PMID 34741731, PMID 42023429, PMID 22634621, PMID 25581159, PMID 28946756, PMID 12542793, PMID 15864738, PMID 20937945, PMID 23982748, PMID 24759263, PMID 25442786, PMID 25749867, PMID 26068866, PMID 26138472, PMID 26290435, PMID 27099766, PMID 27112532, PMID 27423899, PMID 27574516, PMID 27779572, PMID 28143815, PMID 28925994, PMID 29679103, PMID 29776017, PMID 31501122, PMID 32433237, PMID 32453485, PMID 32816215, PMID 33127856, PMID 33165774, PMID 33506875, PMID 33687069, PMID 34324441, PMID 34347960, PMID 34724566, PMID 34870800, PMID 36109639, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 37226224, PMID 37735841, PMID 38258274, PMID 38299639, PMID 39251561

NIH funding

2015 (23), 2014 (19), 2017 (18), 2018 (18), 2025 (18), 2023 (16), 2009 (15), 2008 (12), 2016 (7), 2019 (7), 2005 (3), 2004 (2), R01AR056702 (2), DP3DK106785 (1), K23AR075874 (1)